4-(环庚基氨基)-4-氧代丁酸 | 545349-11-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-(环庚基氨基)-4-氧代丁酸
• 英文名称: N-cycloheptyl-succinamic acid
• 英文别名: N-Cycloheptyl-succinamidsaeure；4-(Cycloheptylamino)-4-oxobutanoic acid
• CAS: 545349-11-9
• 化学式: C₁₁H₁₉NO₃
• mdl: MFCD03387995
• 分子量: 213.277
• InChiKey: XSJLCCURWNGWTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  丁二酸酐 、 环庚胺 生成 4-(环庚基氨基)-4-氧代丁酸
  参考文献：
  名称：

  Going to the movies: cinema development in Singapore

  摘要：

  DOI：

  10.1080/02614360127118

文献信息

• DINUCLEOTIDES
  申请人：OXFORD UNIVERSITY INNOVATION LIMITED

  公开号：US20190015439A1

  公开（公告）日：2019-01-17

  The present invention relates to novel dinucleotides that are useful for the preparation of oligonucleotides. The present invention also relates to novel dinucleotides that are useful therapeutically.

  本发明涉及用于制备寡核苷酸的新型二核苷酸。本发明还涉及在治疗上有用的新型二核苷酸。
• Dinucleotides
  申请人：OXFORD UNIVERSITY INNOVATION LIMITED

  公开号：US11110114B2

  公开（公告）日：2021-09-07

  The present disclosure relates to novel dinucleotides comprising at least two locked nucleosides, one of which is directly attached to the 3′ end of the triazole linker moiety and the other of which is directly linked to the 5′ end of the triazole linker moiety and that are useful for the preparation of oligonucleotides. The disclosed dinucleotides may be used in gene therapy.

  本公开涉及新型二核苷酸，它包含至少两个锁定的核苷，其中一个直接连接到三唑连接分子的 3′端，另一个直接连接到三唑连接分子的 5′端，可用于制备寡核苷酸。所公开的二核苷酸可用于基因治疗。
• siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：US20210147840A1

  公开（公告）日：2021-05-20

  The present invention relates to nucleic acids for inhibiting expression of a target gene in a cell, comprising at least one duplex region that comprises at least a portion of a first strand and at least a portion of a second strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene to be inhibited. The first strand of the nucleic acid has a terminal 5′ (E)-vinylphosphonate nucleotide that is linked to the second nucleotide in the first strand by a phosphodiester linkage.
• siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：US20210155926A1

  公开（公告）日：2021-05-27

  There is provided inter alia a conjugate for inhibiting expression of a target gene in a cell, said conjugate comprising a nucleic acid portion and ligand portions, said nucleic acid portion comprising at least one duplex region that comprises at least a portion of a first RNA strand and at least a portion of a second RNA strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene, said ligand portions comprising a linker moiety and a targeting ligand for in vivo targeting of cells and being conjugated exclusively to the 3′ and/or 5′ ends of one or both RNA strands, wherein the 5′ end of the first RNA strand is not conjugated, wherein: (i) the second RNA strand is conjugated at the 5′ end to the targeting ligand, and wherein (a) the second RNA strand is also conjugated at the 3′ end to the targeting ligand and the 3′ end of the first RNA strand is not conjugated; or (b) the first RNA strand is conjugated at the 3′ end to the targeting ligand and the 3′ end of the second RNA strand is not conjugated; or (c) both the second RNA strand and the first RNA strand are also conjugated at the 3′ ends to the targeting ligand; or (ii) both the second RNA strand and the first RNA strand are conjugated at the 3′ ends to the targeting ligand and the 5′ end of the second RNA strand is not conjugated.